open access

Vol 92, No 3 (2021)
Guidelines / Expert consensus
Published online: 2021-03-31
Get Citation

The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women

Magdalena E. Grzybowska, Tomasz Rechberger, Andrzej Wrobel, Wlodzimierz Baranowski, Klaudia Stangel-Wojcikiewicz, Artur Rogowski, Tomasz Kluz, Elzbieta Narojczyk-Swiesciak, Edyta Wlazlak, Bartlomiej Burzynski, Grzegorz Surkont
DOI: 10.5603/GP.2021.0046
·
Pubmed: 33844243
·
Ginekol Pol 2021;92(3):236-251.

open access

Vol 92, No 3 (2021)
RECOMMENDATIONS
Published online: 2021-03-31

Abstract

Objectives: The aim of the publication was to present the interdisciplinary guidelines of the Urogynecology Section of the
Polish Society of Gynecologists and Obstetricians (PSGO) for the treatment of overactive bladder (OAB) syndrome based
on the available literature, expert knowledge, and everyday practice.
Material and methods: A review of the literature, including current recommendations for the treatment of overactive
bladder syndrome, urinary incontinence, urgency and mixed urinary incontinence, as well as the earlier recommendations
of the PSGO Urogynecology Section, was conducted.
Results: Management of the patients with OAB is presented. Four lines of therapy were identified: 1) educating the patient,
behavioral therapy with pelvic floor muscle training, 2) pharmacotherapy, 3) botulinum toxin injection and tibial nerve
stimulation; and sacral nerve stimulation even though so far it has been used only in selected populations, 4) surgical intervention.
The literature reports which provided supporting evidence and presented various aspects of the therapy were
discussed. OAB pharmacotherapy-related issues which are vital in everyday clinical practice were presented.
Conclusions: A systematic review of the available guidelines and an analysis of OAB (including urgency urinary incontinence)
management were conducted. The Polish Society of Gynecologists and Obstetricians issued the guidelines for the
therapeutic management of OAB patients. The need for an individualized approach was emphasized.

Abstract

Objectives: The aim of the publication was to present the interdisciplinary guidelines of the Urogynecology Section of the
Polish Society of Gynecologists and Obstetricians (PSGO) for the treatment of overactive bladder (OAB) syndrome based
on the available literature, expert knowledge, and everyday practice.
Material and methods: A review of the literature, including current recommendations for the treatment of overactive
bladder syndrome, urinary incontinence, urgency and mixed urinary incontinence, as well as the earlier recommendations
of the PSGO Urogynecology Section, was conducted.
Results: Management of the patients with OAB is presented. Four lines of therapy were identified: 1) educating the patient,
behavioral therapy with pelvic floor muscle training, 2) pharmacotherapy, 3) botulinum toxin injection and tibial nerve
stimulation; and sacral nerve stimulation even though so far it has been used only in selected populations, 4) surgical intervention.
The literature reports which provided supporting evidence and presented various aspects of the therapy were
discussed. OAB pharmacotherapy-related issues which are vital in everyday clinical practice were presented.
Conclusions: A systematic review of the available guidelines and an analysis of OAB (including urgency urinary incontinence)
management were conducted. The Polish Society of Gynecologists and Obstetricians issued the guidelines for the
therapeutic management of OAB patients. The need for an individualized approach was emphasized.

Get Citation

Keywords

overactive bladder; pharmacotherapy; behavioral therapy; physiotherapy; botulinum toxin; urinary incontinence

About this article
Title

The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women

Journal

Ginekologia Polska

Issue

Vol 92, No 3 (2021)

Article type

Guidelines / Expert consensus

Pages

236-251

Published online

2021-03-31

DOI

10.5603/GP.2021.0046

Pubmed

33844243

Bibliographic record

Ginekol Pol 2021;92(3):236-251.

Keywords

overactive bladder
pharmacotherapy
behavioral therapy
physiotherapy
botulinum toxin
urinary incontinence

Authors

Magdalena E. Grzybowska
Tomasz Rechberger
Andrzej Wrobel
Wlodzimierz Baranowski
Klaudia Stangel-Wojcikiewicz
Artur Rogowski
Tomasz Kluz
Elzbieta Narojczyk-Swiesciak
Edyta Wlazlak
Bartlomiej Burzynski
Grzegorz Surkont

References (80)
  1. Haylen BT, de Ridder D, Freeman RM, et al. International Urogynecological Association, International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29(1): 4–20.
  2. Gormley E, Lightner D, Burgio K, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. Journal of Urology. 2012; 188(6S): 2455–2463.
  3. Burkhard FC, Bosch JLHR, Cruz F, et al. Guidelines on Urinary Incontinence. European Association of Urology. https://uroweb.org/guideline/urinary-incontinence/#4 (10.01.2020).
  4. Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017; 11(5): E142–E173.
  5. Radziszewski P, Baranowski W, Nowak-Markwitz E, et al. Wytyczne Zespołu Ekspertów odnośnie postępowania diagnostyczno- terapeutycznego u kobiet z nietrzymaniem moczu i pęcherzem nadreaktywnym. Ginekol Pol. 2010; 81: 789–793.
  6. Skręt A, Kotarski J, Baranowski W, et al. Rekomendacje Polskiego Towarzystwa Ginekologicznego dotyczące profilaktyki oraz leczenia zaburzeń statyki narządów płciowych i wysiłkowego nietrzymania moczu u pacjentek zakwalifikowanych do histerektomii. Ginekol Pol. 2009; 80: 459–465.
  7. Spaczyński M, Radowicki S, Rechberger T, et al. Rekomendacje Polskiego Towarzystwa Ginekologicznego w sprawie diagnostyki i leczenia nietrzymania moczu u kobiet. Ginekol Pol. 2005; 76(11): 848–854.
  8. Rai BP, Cody JD, Alhasso A, et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012; 12: CD003193.
  9. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009; 63(8): 1177–1191.
  10. Subak LL, Wing R, West DS, et al. PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009; 360(5): 481–490.
  11. Hannestad YS, Rortveit G, Daltveit AK, et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG. 2003; 110(3): 247–254.
  12. Zhu J, Hu X, Dong X, et al. Associations Between Risk Factors and Overactive Bladder: A Meta-analysis. Female Pelvic Med Reconstr Surg. 2019; 25(3): 238–246.
  13. Nuotio M, Jylhä M, Koivisto AM, et al. Association of smoking with urgency in older people. Eur Urol. 2001; 40(2): 206–212.
  14. Coyne KS, Cash B, Kopp Z, et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int. 2011; 107(2): 254–261.
  15. Charach G, Greenstein A, Rabinovich P, et al. Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology. 2001; 47(2): 72–76.
  16. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998; 280(23): 1995–2000.
  17. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012; 1: CD005429.
  18. Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007; 51(4): 907–14; discussion 914.
  19. Andersson KE, Cardozo L, Cruz F. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, Wein A. ed. Incontinence, 6th edition. ICUD ICS 2017: 805–958.
  20. Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006; 67(2): 275–280.
  21. Futyma K, Rechberger T. Nadaktywny pęcherz moczowy - nowe możliwości terapeutyczne. Przegląd Urologiczny. 2010; 6(64): 10–13.
  22. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003; 20(6): 392–399.
  23. Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006; 60(6): 745–751.
  24. Chapple C, Fianu-Jonsson A, Indig M, et al. Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg. European Urology. 2007; 52(4): 1195–1203.
  25. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010; 105(1): 58–66.
  26. Tack J, Wyndaele JJ, Ligozio G, et al. A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. Drug Healthc Patient Saf. 2012; 4: 127–139.
  27. Khullar V, Foote J, Seifu Y, et al. Time-to-effect with darifenacin in overactive bladder: a pooled analysis. Int Urogynecol J. 2011; 22(12): 1573–1580.
  28. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004; 45(4): 420–9; discussion 429.
  29. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005; 48(3): 464–470.
  30. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017; 36(2): 414–421.
  31. Takahashi S, Takei M, Asakura H, et al. Clinical Guideline for Female Lower Urinary Tract Symptoms. Low Urin Tract Symptoms. 2016; 8(1): 5–29.
  32. Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013; 67(7): 619–632.
  33. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013; 63(2): 283–295.
  34. Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol. 2013; 13: 45.
  35. Gratzke C, van Maanen R, Chapple C, et al. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018; 74(4): 501–509.
  36. Wróbel A, Kluz T, Surkont G, et al. Perspectives for the pharmacological treatment of overactive bladder syndrome. Ginekol Pol. 2017; 88(9): 504–508.
  37. Sacomani CA, Almeida FG, Silvinato A, et al. Overactive bladder - pharmacological treatment. Rev Assoc Med Bras (1992). 2019; 65(4): 487–492.
  38. Miotła P, Dobruch J, Lipiński M, et al. Diagnostic and therapeutic recommendations for patients with nocturia. Cent European J Urol. 2017; 70(4): 388–393.
  39. Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012; 110(11): 1767–1774.
  40. Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014; 191(4): 1003–1008.
  41. Andersson KE, Sarawate C, Kahler KH, et al. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010; 106(2): 268–274.
  42. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011; 72(2): 186–196.
  43. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther. 2008; 13(4): 241–251.
  44. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007; 178(6): 2488–2494.
  45. Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol. 1996; 41(1): 73–75.
  46. Michel MC, Wetterauer U, Vogel M, et al. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf. 2008; 31(6): 505–514.
  47. Cetinel B, Onal B, Gultekin MH, et al. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial. Int Urol Nephrol. 2019; 51(3): 417–424.
  48. Nitti VW, Chapple CR, Walters C, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013; 189(4): 1388–1395.
  49. White WB, Siddiqui E, Tat T, et al. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018; 12(11): 768–778.e1.
  50. White WB, Chapple C, Gratzke C, et al. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Press Monit. 2018; 23(3): 153–163.
  51. Guay DRp. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag. 2005; 1(2): 157–167.
  52. Malhotra B, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009; 16(33): 4481–4489.
  53. Gorup E, Rifel J, Petek Šter M. Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients. Zdr Varst. 2018; 57(3): 140–147.
  54. Welsh TJ, van der Wardt V, Ojo G, et al. Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews. Drugs Aging. 2018; 35(6): 523–538.
  55. Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013; 69(7): 1485–1496.
  56. Cheng CL, Li JR, Lin CH, et al. Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan. Medicine (Baltimore). 2016; 95(28): e4107.
  57. Yoshida J, Aikawa K, Yoshimura Y, et al. The effects of ovariectomy and estrogen replacement on acetylcholine release from nerve fibres and passive stretch-induced acetylcholine release in female rat bladder. Neurourol Urodyn. 2007; 26(7): 1050–1055.
  58. Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004; 83(10): 892–897.
  59. Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009; 28(1): 47–51.
  60. Serati M, Salvatore S, Uccella S, et al. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009; 55(3): 713–719.
  61. Jiang F, Zhu L, Xu T, et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study. Menopause. 2016; 23(4): 451–457.
  62. Nitti VW, Dmochowski R, Herschorn S, et al. EMBARK Study Group, EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013; 189(6): 2186–2193.
  63. Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013; 64(2): 249–256.
  64. Visco AG, Brubaker L, Jelovsek JE, et al. Pelvic Floor Disorders Network, Pelvic Floor Disorders Network, Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012; 367(19): 1803–1813.
  65. Summary of Product Characteristics Botox®. https://pub.rejestrymedyczne.csioz.gov.pl/ProduktSzczegoly.aspx?id=20166 (28.03.2020).
  66. Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007; 178(4 Pt 1): 1359–1363.
  67. Jo JKi, Kim KN, Kim DW, et al. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol. 2018; 36(2): 305–317.
  68. Nitti V, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017; 197(2S).
  69. Rovner E, Athanasiou S, Choo MS. Surgery for urinary incontinence in women. In: Abrams P, Cardozo L, Wagg A, Wein A. ed. Incontinence 6th edition. ICUD ICS 2017: 1741–1854.
  70. Ramírez-García I, Kauffmann S, Blanco-Ratto L, et al. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial. Neurourol Urodyn. 2019; 38(1): 261–268.
  71. Martin-Garcia M, Crampton J. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). Physiotherapy. 2019; 105(4): 469–475.
  72. Jerez-Roig J, Souza D, Espelt A, et al. Pelvic floor electrostimulation in women with urinary incontinence and/or overactive bladder syndrome: A systematic review. Actas Urol Esp. 2013; 37(7): 429–444.
  73. Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology. 2006; 68(5): 999–1004.
  74. Weil EH, Ruiz-Cerdá JL, Eerdmans PH, et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol. 2000; 37(2): 161–171.
  75. Siegel S, Noblett K, Mangel J, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2018; 199(1): 229–236.
  76. Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA. 2016; 316(13): 1366–1374.
  77. Wróbel AF, Kluz T, Surkont G, et al. Novel biomarkers of overactive bladder syndrome. Ginekol Pol. 2017; 88(10): 568–573.
  78. Wróbel A, Doboszewska U, Rechberger E, et al. Blebbistatin, a Myosin II Inhibitor, Exerts Antidepressant-Like Activity and Suppresses Detrusor Overactivity in an Animal Model of Depression Coexisting with Overactive Bladder. Neurotox Res. 2019; 35(1): 196–207.
  79. Wróbel A, Rechberger T. The influence of Rho-kinase inhibition on acetic acid-induced detrusor overactivity. Neurourol Urodyn. 2017; 36(2): 263–270.
  80. Wróbel A, Miziak B, Bańczerowska-Górska M, et al. The influence of nebivolol on the activity of BRL 37344 - the β3-adrenergic receptor agonist, in the animal model of detrusor overactivity. Neurourol Urodyn. 2019; 38(5): 1229–1240.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl